During the past decade, Lipson Cancer and Blood Center at Rochester General Hospital conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 13 clinical trials were completed, i.e. on average, 260% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lipson Cancer and Blood Center at Rochester General Hospital" #1 sponsor was "Radiation Therapy Oncology Group" with 8 trials, followed by "Alliance for Clinical Trials in Oncology" with 6 trials sponsored, "NSABP Foundation Inc" with 3 trials sponsored, "Novartis Pharmaceuticals" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lipson Cancer and Blood Center at Rochester General Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "NRG Oncology" with 6 trials as a collaborator, "SWOG Cancer Research Network" with 3 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator and "Eastern Cooperative Oncology Group" with 2 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Lipson Cancer and Blood Center at Rochester General Hospital" are "Breast Cancer" (7 trials), "Lung Cancer" (4 trials), "Brain and Central Nervous System Tumors" (3 trials), "Prostate Cancer" (3 trials) and "Metastatic Cancer" (2 trials). Many other conditions were trialed in "Lipson Cancer and Blood Center at Rochester General Hospital" in a lesser frequency.

Most popular intervention types in "Lipson Cancer and Blood Center at Rochester General Hospital" are "Drug" (20 trials), "Radiation" (9 trials), "Other" (6 trials), "Biological" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "doxorubicin hydrochloride" (4 trials), "paclitaxel" (4 trials), "Placebo" (3 trials), "radiation therapy" (3 trials) and "AC regimen" (2 trials). Other intervention names were less common.

The vast majority of trials in "Lipson Cancer and Blood Center at Rochester General Hospital" are 19 trials for "All" genders, 6 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Lipson Cancer and Blood Center at Rochester General Hospital". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Lipson Cancer and Blood Center at Rochester General Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Lipson Cancer and Blood Center at Rochester General Hospital, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".